NCT02128061 Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ Status COMPLETED Phase PHASE3
NCT02126553 Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Status COMPLETED Phase PHASE2
NCT02112175 Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM Status COMPLETED Phase PHASE3
NCT02086604 Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Status COMPLETED Phase PHASE1
NCT02086552 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Status COMPLETED Phase PHASE2
NCT02077959 Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Status TERMINATED Phase PHASE1
NCT02077166 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT02076009 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Status COMPLETED Phase PHASE3
NCT02075021 Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma Status TERMINATED Phase PHASE1/PHASE2
NCT02060656 Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Status UNKNOWN Phase PHASE2
NCT02041325 Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias Status COMPLETED Phase PHASE2
NCT02038153 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Status TERMINATED Phase PHASE1/PHASE2
NCT02036502 A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) Status TERMINATED Phase PHASE1
NCT02030483 Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma Status TERMINATED Phase PHASE1
NCT02018523 Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer Status TERMINATED Phase PHASE1
NCT02005289 Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Status COMPLETED Phase PHASE2
NCT01998971 A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma Status COMPLETED Phase PHASE1
NCT01996865 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. Status COMPLETED Phase PHASE3
NCT01995669 Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT01985477 Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma Status TERMINATED Phase PHASE1